Company Filing History:
Years Active: 2013
Title: David Brooks - Innovator in Antibody Development
Introduction
David Brooks is an accomplished inventor based in Concord, MA (US). He has made significant contributions to the field of biomedical research, particularly in the development of antibodies for diagnostic and therapeutic applications.
Latest Patents
David Brooks holds a patent for "IGF-1R specific antibodies useful in the detection and diagnosis of cellular proliferative disorders." This invention relates to mammalian antibodies, designated 12B1, and antigen-binding portions that specifically bind to the insulin-like growth factor I receptor (IGF-IR), preferably human IGF-IR. The patent also includes chimeric, bispecific, and derivatized single-chain antibodies derived from the disclosed antibodies. Additionally, it covers nucleic acid molecules encoding these mammalian antibodies, as well as methods of use for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with IGF-1R expression.
Career Highlights
David Brooks is currently associated with Merck Sharp & Dohme Corp., where he continues to advance his research in antibody development. His work has the potential to significantly impact the diagnosis and treatment of various cancers and other proliferative disorders.
Collaborations
Throughout his career, David has collaborated with notable colleagues, including Liliane Goetsch and Michael Chastain. These partnerships have fostered innovation and contributed to the success of his research endeavors.
Conclusion
David Brooks is a prominent inventor whose work in antibody development is paving the way for advancements in medical diagnostics and therapeutics. His contributions are vital to the ongoing fight against oncogenic disorders.